Page last updated: 2024-11-12

sk&f 107647

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SK&F 107647: a synthetic hematoregulatory peptide that shares biological and/or modulatory activities with natural hematopoetic cytokines [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9898394
CHEMBL ID412415
SCHEMBL ID609834
MeSH IDM0228151

Synonyms (20)

Synonym
sb-107647
skf-107647
glaspimod
CHEMBL412415
sk&f 107647
n(sup 2),n(sup 2)'-((2s,7s)-2,7-bis((2s)-3-carboxy-2-((2s)-4-carboxy-2-((2s)-5-oxo-2-pyrrolidinecarboxamido)butyramido)propionamido)octanedioyl)di-l-lysine
glaspimod [inn:ban]
(s)-5-oxo-l-prolyl-l-alpha-glutamyl-l-alpha-aspartyl-n8-(5-amino-1-carboxypentyl)-8-oxo-n7-(n-(n-(5-oxo-l-prolyl)-l-alpha-glutamyl)-l-alpha-aspartyl)-2,7,8-triaminooctanoyl-l-lysine
unii-198e564v9f
sk&f-107647
198e564v9f ,
l-lysine, 5-oxo-l-prolyl-l-alpha-glutamyl-l-alpha-aspartyl-n8-(5-amino-1-carboxypentyl)-8-oxo-n7-(n-(n-(5-oxo-l-prolyl)-l-alpha-glutamyl)-l-alpha-aspartyl)-2,7,8-triaminooctanoyl-, (s)-
134143-28-5
SCHEMBL609834
glaspimod [inn]
l-lysine, n2,n7-bis(5-oxo-l-prolyl-l-.alpha.-glutamyl-l-.alpha.-aspartyl)-(2s,7s)-2,7-diaminooctanedioylbis-
(2s)-6-amino-2-[[(2s,7s)-8-[[(1s)-5-amino-1-carboxypentyl]amino]-2,7-bis[[(2s)-3-carboxy-2-[[(2s)-4-carboxy-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]butanoyl]amino]propanoyl]amino]-8-oxooctanoyl]amino]hexanoic acid
Q27252083
(4s,7s,10s,15s,18s,21s)-10,15-bis(((s)-5-amino-1-carboxypentyl)carbamoyl)-7,18-bis(carboxymethyl)-5,8,17,20-tetraoxo-4,21-bis((s)-5-oxopyrrolidine-2-carboxamido)-6,9,16,19-tetraazatetracosanedioic acid
AKOS040746858

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"W(b)), body-weight normalized human pharmacokinetic data were reasonably predicted using either the body weight normalized rat or the dog data."( Interspecies pharmacokinetics of a novel hematoregulatory peptide (SK&F 107647) in rats, dogs, and oncologic patients.
Boppana, V; Brocks, DR; Citerone, DR; Davies, BE; Freed, MI; Jorkasky, DK; Levitt, B; Martin, DE; Mehdi, N; Nemunaitis, J; Sellers, TS, 1996
)
0.53

Compound-Compound Interactions

ExcerptReferenceRelevance
" However, when SK&F 107647 was administered in combination with low doses of amphotericin B, there was a significant reduction in organism burden in the lungs, liver, spleen, and kidneys compared with the burdens in the organs of untreated control animals and in the lungs and kidneys compared with the burdens in the lungs and kidneys of animals treated with amphotericin B alone."( Effects of the hematoregulatory peptide SK&F 107647 alone and in combination with amphotericin B against disseminated candidiasis in persistently neutropenic rabbits.
Gonzalez, C; Lee, J; Lyman, CA; Schneider, M; Walsh, TJ, 1999
)
0.92

Dosage Studied

ExcerptRelevanceReference
" Additionally, significant increases in survival in non-irradiated immunocompetent mice dosed by oral gavage were observed."( Efficacy of the hematoregulatory peptide SK&F 107647 in experimental systemic Candida albicans infections in normal and immunosuppressed mice.
Actor, P; Bhatnagar, PK; DeMarsh, PL; Frey, CL; Koltin, Y; Petteway, SR; Sucoloski, SK,
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID44633Neutralization of colony - stimulating activity was determined by incubating supernatants from stromal cells stimulated by compound (1000 ng/mL) with an antibody raised against KC[38-72].1997Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
Design of low molecular weight hematoregulatory agents from the structure-activity relationship of a dimeric pentapeptide.
AID225220In vitro ability to induce a hematopoietic synergistic factor from a murine stromal cell line at 10.0 ug/mL2000Bioorganic & medicinal chemistry letters, Mar-20, Volume: 10, Issue:6
Novel peptidomimetic hematoregulatory compounds.
AID225217In vitro ability to induce a hematopoietic synergistic factor from a murine stromal cell line at 0.10 ug/mL2000Bioorganic & medicinal chemistry letters, Mar-20, Volume: 10, Issue:6
Novel peptidomimetic hematoregulatory compounds.
AID225219In vitro ability to induce a hematopoietic synergistic factor from a murine stromal cell line at 1.0 ug/mL2000Bioorganic & medicinal chemistry letters, Mar-20, Volume: 10, Issue:6
Novel peptidomimetic hematoregulatory compounds.
AID44630Relative potency for induction of Colony-Stimulating activity(CSA) of C6 stromal line.1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Structure-activity relationships of novel hematoregulatory peptides.
AID44634HSF produced by bone marrow-derived stromal cell lines C6.4 on stimulation with the compound at (1000 ng/mL) was determined in vitro in an GM-CFC assay.1997Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
Design of low molecular weight hematoregulatory agents from the structure-activity relationship of a dimeric pentapeptide.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's11 (78.57)18.2507
2000's3 (21.43)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.62 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (6.67%)5.53%
Reviews2 (13.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]